Video length: 1:11
[Tile text, Findings Prompt Changing Guidelines for Care of Opioid Exposed Babies]
Dr. Jones speaking: So, in 2010 we published the Mother, Child, which was published in the New England Journal of Medicine. And what the data showed, was that compared to methadone and buprenorphine given to pregnant women who had opioid use disorders, our mean outcomes were focused on the neonate. Of the five primary outcome measures that we had there was not a statistically significant difference in the proportions of babies that required treatment for neonatal abstinence syndrome between methadone and buprenorphine.
[Tile text, Babies exposed to buprenorphine have less severe NAS symptoms than methadone exposed babies.]
So, if you were a buprenorphine exposed baby, you needed eighty-nine percent less medication to treat your, neonatal abstinence syndrome compared to being a methadone exposed baby. Buprenorphine exposed babies also stayed in the hospital for a significantly shorter period of time than methadone exposed babies.
[End slate with HHS and NIDA logo and website, www.drugabuse.gov]